Nasal Drug Delivery Technology Market Share

Nasal Drug Delivery Technology Market Share

The market of nasal drug delivery technology is highly fragmented due to the presence of large international corporations and smaller to medium companies competing for a share of the market. A notable portion of the market strategy centers on the constant introduction of products that apply multiple technologies. It is important to recognize that the leading companies in this industry wield a lot of power in this industry and, in many cases, provide the directions for its development due to their large investments in R&D. Moreover, strategic partnerships, mergers and acquisitions are also instrumental in achieving competitiveness and scale in response to changing market and regulatory conditions.
 

Nasal Drug Delivery Technology Market Companies

Some of the eminent market participants operating in the nasal drug delivery technology industry include:

• Aegis Therapeutics
• AptarGroup
• Boehringer Ingelheim
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• GlaxoSmithKline
• Horizon Therapeutics
• Johnson & Johnson
• Merck
• Nasal Technologies
• Neuralstem
• Pfizer
• Regeneron Pharmaceuticals
• Takeda Pharmaceutical Company
• XenoPort
   

USPs for the top market players:

• AptarGroup is a market leader in the pharmaceuticals industry, specializing in smart nasal spray technologies that allow for accurate and controlled quantity dosage.
   
• Boehringer Ingelheim apply their formulation science knowledge to develop potent corticosteroids for the treatment of asthma and chronic obstructive pulmonary diseases (COPD) to ensure the drugs work quickly with fewer side effects.
   
• F. Hoffmann-La Roche AG systems are designed with a focus on increased bioavailability and limited systemic exposure, making them ideal for the treatment of precision medicine-based therapies for cancer and other rare diseases.
   
• Pfizer is actively involved in the development of new systems and methods of associative nasal drug delivery that are user-friendly whilst improving clinical outcomes.